Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Characteristics and treatment regimens across ERS SHARP severe asthma registries

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{dbbf82b661134b43b922b5d47a098780,
title = "Characteristics and treatment regimens across ERS SHARP severe asthma registries",
abstract = "Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0{\%} (Poland and Sweden) to 9.5{\%} (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s {\%} predicted was 20.9{\%} (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0{\%} (Belgium) to 63.0{\%} (Sweden) and from 9.1{\%} (Denmark) to 56.1{\%} (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.",
author = "{van Bragt}, {Job J M H} and Adcock, {Ian M} and Bel, {Elisabeth H D} and Gert-Jan Braunstahl and {Ten Brinke}, Anneke and John Busby and Canonica, {Giorgio W} and Hui Cao and Chung, {Kian Fan} and Zsuzsanna Csoma and Barbro Dahl{\'e}n and Elizabeth Davin and Susanne Hansen and Enrico Heffler and Ildiko Horvath and Stephanie Korn and Maxim Kots and Piotr Kuna and Namhee Kwon and Renaud Louis and Vicente Plaza and Celeste Porsbjerg and David Ramos-Barbon and Richards, {Levi B} and Sabina Škrgat and Sont, {Jacob K} and Vijverberg, {Susanne J H} and Weersink, {Els J M} and Valentyna Yasinska and Wagers, {Scott S} and Ratko Djukanovic and {Maitland-van der Zee}, {Anke H} and {SHARP Clinical Research Collaboration}",
note = "Copyright {\circledC}ERS 2020.",
year = "2020",
month = "1",
doi = "10.1183/13993003.01163-2019",
language = "English",
volume = "55",
journal = "The European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

RIS

TY - JOUR

T1 - Characteristics and treatment regimens across ERS SHARP severe asthma registries

AU - van Bragt, Job J M H

AU - Adcock, Ian M

AU - Bel, Elisabeth H D

AU - Braunstahl, Gert-Jan

AU - Ten Brinke, Anneke

AU - Busby, John

AU - Canonica, Giorgio W

AU - Cao, Hui

AU - Chung, Kian Fan

AU - Csoma, Zsuzsanna

AU - Dahlén, Barbro

AU - Davin, Elizabeth

AU - Hansen, Susanne

AU - Heffler, Enrico

AU - Horvath, Ildiko

AU - Korn, Stephanie

AU - Kots, Maxim

AU - Kuna, Piotr

AU - Kwon, Namhee

AU - Louis, Renaud

AU - Plaza, Vicente

AU - Porsbjerg, Celeste

AU - Ramos-Barbon, David

AU - Richards, Levi B

AU - Škrgat, Sabina

AU - Sont, Jacob K

AU - Vijverberg, Susanne J H

AU - Weersink, Els J M

AU - Yasinska, Valentyna

AU - Wagers, Scott S

AU - Djukanovic, Ratko

AU - Maitland-van der Zee, Anke H

AU - SHARP Clinical Research Collaboration

N1 - Copyright ©ERS 2020.

PY - 2020/1

Y1 - 2020/1

N2 - Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.

AB - Little is known about the characteristics and treatments of patients with severe asthma across Europe, but both are likely to vary. This is the first study in the European Respiratory Society Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) Clinical Research Collaboration and it is designed to explore these variations. Therefore, we aimed to compare characteristics of patients in European severe asthma registries and treatments before starting biologicals.This was a cross-sectional retrospective analysis of aggregated data from 11 national severe asthma registries that joined SHARP with established patient databases.Analysis of data from 3236 patients showed many differences in characteristics and lifestyle factors. Current smokers ranged from 0% (Poland and Sweden) to 9.5% (Belgium), mean body mass index ranged from 26.2 (Italy) to 30.6 kg·m-2 (the UK) and the largest difference in mean pre-bronchodilator forced expiratory volume in 1 s % predicted was 20.9% (the Netherlands versus Hungary). Before starting biologicals patients were treated differently between countries: mean inhaled corticosteroid dose ranged from 700 to 1335 µg·day-1 between those from Slovenia versus Poland when starting anti-interleukin (IL)-5 antibody and from 772 to 1344 µg·day-1 in those starting anti-IgE (Slovenia versus Spain). Maintenance oral corticosteroid use ranged from 21.0% (Belgium) to 63.0% (Sweden) and from 9.1% (Denmark) to 56.1% (the UK) in patients starting anti-IL-5 and anti-IgE, respectively.The severe asthmatic population in Europe is heterogeneous and differs in both clinical characteristics and treatment, often appearing not to comply with the current European Respiratory Society/American Thoracic Society guidelines definition of severe asthma. Treatment regimens before starting biologicals were different from inclusion criteria in clinical trials and varied between countries.

U2 - 10.1183/13993003.01163-2019

DO - 10.1183/13993003.01163-2019

M3 - Journal article

VL - 55

JO - The European Respiratory Journal

JF - The European Respiratory Journal

SN - 0903-1936

IS - 1

ER -

ID: 59244844